Augustine Therapeutics Successfully Raises EUR 78 Million
Leuven, Belgium – Augustine Therapeutics NV, a pioneering biotechnology company dedicated to developing innovative therapies for neuromuscular, neurodegenerative, and cardio-metabolic diseases, has successfully completed an oversubscribed Series A financing round, raising EUR 78 million (USD 85 million).
Key Investors in Series A Financing
The financing round was co-led by Novo Holdings and Jeito Capital, with support from existing investors such as Asabys Partners, Eli Lilly and Company, and others. This robust financial backing will fuel Augustine’s ongoing research and development efforts, bringing its promising therapies to patients faster.
Advancing Innovative Therapies
Proceeds from this financing will primarily support the clinical development of Augustine's lead candidate, AGT-100216, which is poised to enter Phase I trials soon. This candidate aims to address Charcot-Marie-Tooth (CMT) disease, the most prevalent hereditary disorder affecting the peripheral nervous system, which impacts approximately three million individuals worldwide.
Development of HDAC6 Inhibitors
Augustine Therapeutics is exploring the potential of next-generation HDAC6 inhibitors (HDAC6i) for treating various significant cardio-metabolic and neurodegenerative diseases. These therapies strategically inhibit the HDAC6 enzyme without compromising its beneficial non-catalytic functions, setting them apart from traditional approaches.
Strategic Leadership and Vision
Under the leadership of newly appointed CEO, Gerhard Koenig, PhD, who has extensive biopharma experience, Augustine is set to innovate in the therapeutic landscape. Dr. Koenig expressed his excitement about the financing, remarking on the unique mechanism of action of their therapies and the significant potential for addressing chronic diseases.
Collaboration with Investors
Investor partners from Novo Holdings and Jeito Capital highlighted their confidence in Augustine’s rigorous approach to medicinal chemistry. They believe it holds the potential for best-in-class treatment options that could significantly improve patient outcomes in areas with limited options.
Growth Prospects and Future Plans
As Augustine expands its operations, it plans to tap into the rich talent pool and unique ecosystem in Denmark. This strategic move aligns with its mission to develop HDAC6 inhibitors that could transform treatment options for patients suffering from various conditions.
Continuing Commitment to Innovation
Augustine Therapeutics is steadfast in its commitment to creating groundbreaking solutions for neuromuscular diseases. The recent funding, along with collaborations with esteemed investors, reinforces the company’s potential to lead in the biotech industry and significantly enhance patient care.
Frequently Asked Questions
What is Augustine Therapeutics focused on?
Augustine Therapeutics specializes in developing therapies for neuromuscular, neurodegenerative, and cardio-metabolic diseases.
How much funding did Augustine Therapeutics raise?
They raised EUR 78 million (USD 85 million) in their recent Series A financing round.
What is AGT-100216?
AGT-100216 is Augustine’s lead candidate targeting Charcot-Marie-Tooth (CMT) disease, currently entering Phase I trials.
Who led the recent financing round?
Novo Holdings and Jeito Capital co-led the financing, with support from other investors.
What are HDAC6 inhibitors?
HDAC6 inhibitors are a novel class of therapies being developed to selectively target HDAC6, addressing various diseases effectively.
